Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Swedish Orphan buys Dova for $915mm

Executive Summary

Swedish Orphan Biovitrum AB (Sobi) signed a definitive agreement to acquire Dova Pharmaceuticals Inc., a public three-year-old hematology drug company. The total potential value of the deal could hit $915mm, including $27.50 per Dova share in cash (a 55% premium to the 10-day pre-announcement market average) and contingent value rights entitling Dova shareholders to $1.50 per share.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register